Belal Howidi
Expertise:
Belal Howidi is a Research Associate in the value and evidence division at EVERSANA with experience in literature reviews, manuscripts, RWE research, value dossiers, CADTH/INESSS submissions, and HEOR modelling.
Belal began his professional journey with EVERSANA in September 2022. Since then, Belal has been involved in various projects including targeted literature reviews, systematic literature reviews, value dossier development, and CADTH submissions, all of which cover a wide spectrum of disease spaces (e.g., Alzheimer’s disease, psoriasis, depression, breast cancer, and rare diseases such as transthyretin-mediated amyloidosis). More recently, Belal has been involved in medical writing and modelling development, such as budget-impact modelling and pharmacoeconomic adaptations for Canadian submissions.
Belal holds an MSc in Neuroscience from McGill University, and an Honours BSc Specialization in Psychology with a Major in Pharmacology from the University of Western Ontario.
Articles by Belal Howidi
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard of care for patients after 1L CDK4/6i treatment. Understanding the real-world effectiveness of subsequent therapies may help to identify an unmet need in this patient population. The Value & Evidence team at EVERSANA (Sarah Kane, Belal Howidi, Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo) synthesized the effectiveness of treatments received in the real-world setting […]